You are using an older browser version. Please use a supported version for the best MSN experience.

Venus Remedies gets European patent for drug-resistant infection medicine

LiveMint logoLiveMint 03-06-2014 CH Unnikrishnan

Mumbai: Venus Medicine Research Centre, the discovery research arm of drugmaker Venus Remedies Ltd, has been granted a product patent by the European Union Patent Office (EPO) for a novel antibiotic product, code named VRP008, to treat drug-resistant bacterial infection.

VRP008 is a combination of anti-bacterial drug carbapenem and a novel amino glycoside—a new chemical entity. It is the outcome of eight years of research by Venus, which has been focusing on anti-microbial resistance.

“We, at Venus Medial Research Centre, have been working dedicatedly to provide effective and affordable solution to the compounding problem of anti-microbial resistance ever since we identified this problem more than 10 years ago,” said Manu Chaudhary, joint managing director of Venus Remedies in a statement on Tuesday.

Venus had been granted European patents for three other drug candidates in the same area earlier. “Once launched, VRP008 will be one of the best solutions for hospital infections,” added Chaudhary.

According to Venus Remedies, the new drug is designed for mixed multi-drug infections for paediatric, geriatric and adult patients.

Currently, at least 25,000 people die each year in the European Union from infections due to multi-drug-resistant organisms. The economic impact of this is estimated at €1.5 billion annually. Infections caused by these antibiotic-resistant bacteria result in approximately 2.5 million extra hospital days annually in Europe. In 2009, the global anti-infectives market generated revenues of $79.12 billion, according to industry data. Overall growth in this market for 2009 to 2024 is estimated to be at 6.76% to a total sales of $99.13 billion.

More From LiveMint

image beaconimage beaconimage beacon